Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma (Q85049476)
Jump to navigation
Jump to search
scientific article published on 05 October 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma |
scientific article published on 05 October 2011 |
Statements
Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma (English)
Kevin B Kim
Jason Chesney
Douglas Robinson
Humphrey Gardner
Michael M Shi
John M Kirkwood
5 October 2011